Home/Top cited articles

Top cited articles

Acceptance rate:
26%
Time to first decision with review (median):
44 days*
Acceptance to publication:
17 days*
Impact Factor (JCR):
4.463
Citescore:
7
Citescore rank:
22/193
More journal metrics
How we get these metrics
*median number of days

Autopsy in suspected COVID-19 cases
Hanley, Brian; Lucas, Sebastian B.; Youd, Esther; et al
10.1136/jclinpath-2020-206522

Histopathological observations in COVID-19: a systematic review
Deshmukh, Vishwajit; Motwani, Rohini; Kumar, Ashutosh; et al
10.1136/jclinpath-2020-206995

Gene of the month: the 2019-nCoV/SARS-CoV-2 novel coronavirus spike protein
Pillay, Tahir S.
10.1136/jclinpath-2020-206658

Cancer diagnostic rates during the 2020 ‘lockdown’, due to COVID-19 pandemic, compared with the 2018-2019: an audit study from cellular pathology
De Vincentiis, Ludovica; Carr, Richard A.; Mariani, Maria Paola; et al
10.1136/jclinpath-2020-206833

Rosai-Dorfman disease: an overview
Bruce-Brand, Cassandra; Schneider, Johann W.; Schubert, Pawel
10.1136/jclinpath-2020-206733

Cystic neutrophilic granulomatous mastitis: an update
Wu, Jessie M.; Turashvili, Gulisa
10.1136/jclinpath-2019-206180

Tumour immune microenvironment biomarkers predicting cytotoxic chemotherapy efficacy in colorectal cancer
Wilkinson, Kate; Ng, Weng; Roberts, Tara Laurine; et al
10.1136/jclinpath-2020-207309

Fatal pulmonary fibrosis: a post-COVID-19 autopsy case
Schwensen, Hanna Ferlov; Borreschmidt, Line Kristine; Storgaard, Merete; et al
10.1136/jclinpath-2020-206879

Current and future applications of artificial intelligence in pathology: a clinical perspective
Rakha, Emad A.; Toss, Michael; Shiino, Sho; et al
10.1136/jclinpath-2020-206908

Low-grade oncocytic tumour expands the spectrum of renal oncocytic tumours and deserves separate classification: a review of 23 cases from a single tertiary institute
Akgul, Mahmut; Al-Obaidy, Khaleel, I; Cheng, Liang; et al
10.1136/jclinpath-2021-207478

Towards effective diagnostic assays for COVID-19: a review
Venter, Marietjie; Richter, Karin
10.1136/jclinpath-2020-206685

COVID-19 salivary signature: diagnostic and research opportunities
Sapkota, Dipak; Soland, Tine Merete; Galtung, Hilde Kanli; et al
10.1136/jclinpath-2020-206834

Multiplex immunohistochemistry/immunofluorescence (mIHC/IF) for PD-L1 testing in triple-negative breast cancer: a translational assay compared with conventional IHC
Yeong, Joe; Tan, Tira; Chow, Zi Long; et al
10.1136/jclinpath-2019-206252

Analysis of real-world PD-L1 IHC 28-8 and 22C3 pharmDx assay utilisation, turnaround times and analytical concordance across multiple tumour types
Krigsfeld, Gabriel S.; Prince, Emily A.; Pratt, James; et al
10.1136/jclinpath-2020-206466

Medulloblastoma cancer stem cells: molecular signatures and therapeutic targets
Bahmad, Hisham F.; Poppiti, Robert J.
10.1136/jclinpath-2019-206246

Molecules in pathogenesis: angiotensin converting enzyme 2 (ACE2)
Wiese, Owen; Zemlin, Annalise E.; Pillay, Tahir S
10.1136/jclinpath-2020-206954

Placental microbial-metabolite profiles and inflammatory mechanisms associated with preterm birth
Parris, Kerry M.; Amabebe, Emmanuel; Cohen, Marta C.; et al
10.1136/jclinpath-2020-206536

Histological and molecular diversity and heterogeneity of precancerous lesions associated with inflammatory bowel diseases
Gui, Xianyong; Kobel, Martin; Ferraz, Jose G. P.; et al
10.1136/jclinpath-2019-206247

Platelet aggregates, a marker of severe COVID-19 disease
Rampotas, Alexandros; Pavord, Sue
10.1136/jclinpath-2020-206933

Implementing NGS-based BRCA tumour tissue testing in FFPE ovarian carcinoma specimens: hints from a real-life experience within the framework of expert recommendations
Rivera, Daniela; Paudice, Michele; Gismondi, Viviana; et al
10.1136/jclinpath-2020-206840